for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Newron Pharmaceuticals SpA

NWRN.S

Latest Trade

7.54CHF

Change

0.54(+7.71%)

Volume

114,586

Today's Range

7.00

 - 

7.64

52 Week Range

5.33

 - 

9.78

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7.00
Open
7.08
Volume
114,586
3M AVG Volume
0.48
Today's High
7.64
Today's Low
7.00
52 Week High
9.78
52 Week Low
5.33
Shares Out (MIL)
17.85
Market Cap (MIL)
124.63
Forward P/E
-4.41
Dividend (Yield %)
--

Latest Developments

More

Newron Pharmaceuticals H1 Net Loss Widens To EUR 14.0 Mln

Newron Pharmaceuticals Reiterates Guidance

Newron Pharmaceuticals FY Net Loss Widens To EUR 15.04 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Industry

Biotechnology & Drugs

Contact Info

via Ludovico Ariosto 21

+39.02.6103461

https://www.newron.com/

Executive Leadership

Ulrich Kostlin

Chairman, Non-Executive Director

Stefan Weber

Chief Executive Officer, Executive Director, Investor Relations Officer

Roberto Galli

Vice President Finance

Dennis Dionne

Vice President Commercial Affairs

Marco Caremi

Executive Vice President Business Development

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.040

2017

-0.320

2018

-0.840

2019(E)

-1.448
Price To Earnings (TTM)
--
Price To Sales (TTM)
26.70
Price To Book (MRQ)
2.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
22.73
LT Debt To Equity (MRQ)
22.40
Return on Investment (TTM)
-37.63
Return on Equity (TTM)
-34.42

Latest News

Latest News

BRIEF-Newron Pharmaceuticals H1 Net Loss Widens To EUR 14.0 Mln

* H1 NET LOSS OF EUR 14.0 MILLION, COMPARED TO EUR 7.6 MILLION IN SAME PERIOD IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron: Zambon And Valeo Pharma Launch Onstryv For Parkinson's disease In Canada

* DGAP-NEWS: NEWRON'S COMMERCIALIZATION PARTNER ZAMBON AND VALEO PHARMA ANNOUNCE THE LAUNCH OF ONSTRYV(R) (SAFINAMIDE) FOR PARKINSON'S DISEASE IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals Reiterates Guidance

* REITERATES GUIDANCE IT GAVE AT FULL YEAR RESULTS ON MARCH 5, 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Newron delays schizophrenia drug trial after FDA raises concerns

Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system (CNS) events that have emerged in rats and dogs.

BRIEF-Newron Pharmaceuticals Provides Update On Regulatory Status Of Evenamide

* PROVIDES UPDATE ON REGULATORY STATUS OF EVENAMIDE FOR TREATMENT OF SCHIZOPHRENIA

BRIEF-Newron Pharmaceuticals FY Net Loss Widens To EUR 15.04 Million

* FY TOTAL REVENUES DECREASED TO EUR 4.0 MILLION FROM EUR 13.4 MILLION (2017)

BRIEF-Newron Completes Patient Enrollment In Pivotal STARS Study

* POSITIVE STUDY RESULTS MAY LEAD TO APPROVAL OF FIRST DRUG TO BENEFIT A KEY SYMPTOM OF RETT SYNDROME, A SEVERE NEURO-DEVELOPMENTAL ORPHAN DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals: Commercialization Partner Zambon With Valeo Pharma Announce Approval Of Onstryv® (Safinamide) For Parkinson’S Disease In Canada

* NEWRON PHARMACEUTICALS: COMMERCIALIZATION PARTNER ZAMBON TOGETHER WITH VALEO PHARMA ANNOUNCE THE APPROVAL OF ONSTRYV® (SAFINAMIDE) FOR PARKINSON’S DISEASE IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals: Zambon Announces Approval And ARTG Listing Of Safinamide In Australia

* ZAMBON ANNOUNCES APPROVAL AND ARTG LISTING OF SAFINAMIDE IN AUSTRALIA FOR TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals H1 Net Loss Of EUR 7.6 Mln

* H1 NET LOSS OF EUR 7.6 MILLION VERSUS PROFIT OF EUR 1.6 MILLION H1 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals Provides Update On STARS Clinical Study With Sarizotan For Treatment Of Rett Syndrome

* PROVIDES UPDATE ON STARS CLINICAL STUDY WITH SARIZOTAN FOR TREATMENT OF RETT SYNDROME

BRIEF-Newron Pharmaceuticals FY Net Loss Narrows To EUR 5.28 Million

* FY TOTAL REVENUES SUBSTANTIALLY INCREASED TO EUR 13.4 MILLION FROM EUR 6.7 MILLION (2016)

BRIEF-Newron Pharmaceuticals: Current Cash Position At Approx EUR 60 Mln

* CURRENT CASH POSITION AFTER COMPLETING PRIVATE PLACEMENT IN SEPTEMBER 2017 IS APPROX EUR60M Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron ‍raises CHF 27.0 mln in a private placement of new shares​

* RAISES CHF 27.0 MILLION IN A PRIVATE PLACEMENT OF NEW SHARES

BRIEF-Newron ‍launches a private placement of new shares​

* PRIVATE PLACEMENT OF UP TO 2.0 MILLION NEW SHARES TO INSTITUTIONAL INVESTORS (UP TO 12.6% OF SHARE CAPITAL) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals H1 ‍net result swings to profit of EUR 1.5 mln​

* H1 NET PROFIT OF EUR 1.5 MILLION, COMPARED TO A LOSS OF EUR 8.8 MILLION IN SAME PERIOD IN 2016

BRIEF-Newron Pharmaceuticals: Xadago available in U.S. for Parkinson's disease patients​

* XADAGO(R) (SAFINAMIDE) NOW AVAILABLE IN U.S. FOR PARKINSON'S DISEASE PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals receives 11.3 million euros milestone payments for US approval of Xadago

* RECEIVES EUR11.3M MILESTONE PAYMENTS FOR U.S. APPROVAL OF XADAGO (SAFINAMIDE) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals: Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago in Canada

* Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals: XADAGO to be introduced in Portugal

* ZAMBON S.p.A., and partner Newron Pharmaceuticals S.p.A., introduce XADAGO (Safinamide) for patients in the middle to late stage of Parkinson's disease in Portugal

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up